APP and Alzheimer disease: In those trial subjects whose levels of AβPP-derived iAβ will cross the T1 threshold, the AβPP-independent iAβ generation pathway would become operational, and its product will rapidly accumulate, cross the Ts threshold, and trigger the manifestation of the symptoms of AD.